Type 1 diabetes in adults: New NICE guidance on diagnosis and management

Abstract

The barrier of iatrogenic hypoglycaemia has limited the utility and safety of conventional diabetes medications. Novel agents for type 2 diabetes aim to surmount the impediment of iatrogenic hypoglycaemia and unmask the full realisation and benefits of achieving sustained euglycaemia over a lifetime of diabetes.This review aims to critically consider the risk of iatrogenic hypoglycaemia allied with newer agents for type 2 diabetes, used alone and in combination with other diabetes therapies, and how this risk can be minimised.